Avacta Group Plc (AVCTF)

0.5506 0.0000 (0.00%) At close: 03:22PM EDT

Avacta Group Plc

Thorp Arch Estate
Unit 20 Ash Way
Wetherby LS23 7FA
United Kingdom
44 1904 217 070
https://www.avacta.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 154

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christina Marie Coughlin B.S., M.D., Ph.D.	CEO, Interim Chief Medical Officer and Director	67.41k	N/A	1970
Mr. Tony Gardiner	CFO, Company Secretary & Executive Director	520.21k	N/A	1971
Ms. Emma Wright	Group In-House Counsel	N/A	N/A	N/A
Mr. Michael Vinegrad	Group Communications Director	N/A	N/A	N/A
Mr. R. Craig Slater FCA	Chief Operating Officer of Diagnostics	87.76k	N/A	1964
Dr. Matt Johnson	Chief Scientific Officer of Diagnostics	N/A	N/A	N/A
Mr. David Wilson	Chief Commercial Officer of Diagnostics	N/A	N/A	N/A
Ms. Karen Harrison	Chief Operating Officer of Therapeutics Division	N/A	N/A	N/A
Ms. Anne McGurk	Joint Managing Director of Launch Diagnostics	N/A	N/A	N/A
Mr. Ian Jones	Joint Managing Director of Launch Diagnostics	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Corporate governance

Avacta Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.